Center-Authored Papers

Filters: Author is Mariotto, Angela  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
United States
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.  2009.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.. Journal of the National Cancer Institute. 101(6):374-83. Abstract
Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, DiTommaso D, Karnofski K, Gulati R, Penson DF et al..  2008.  Quantifying the role of PSA screening in the US prostate cancer mortality decline.. Cancer causes & control : CCC. 19(2):175-81. Abstract
Tumor Markers, Biological
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.  2009.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.. Journal of the National Cancer Institute. 101(6):374-83. Abstract
Time Factors
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.  2009.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.. Journal of the National Cancer Institute. 101(6):374-83. Abstract
Shared Resources
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.  2009.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.. Journal of the National Cancer Institute. 101(6):374-83. Abstract
Sensitivity and Specificity
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.  2009.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.. Journal of the National Cancer Institute. 101(6):374-83. Abstract
SEER Program
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.  2009.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.. Journal of the National Cancer Institute. 101(6):374-83. Abstract
Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, DiTommaso D, Karnofski K, Gulati R, Penson DF et al..  2008.  Quantifying the role of PSA screening in the US prostate cancer mortality decline.. Cancer causes & control : CCC. 19(2):175-81. Abstract
Risk Factors
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.  2009.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.. Journal of the National Cancer Institute. 101(6):374-83. Abstract
Risk Assessment
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.  2009.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.. Journal of the National Cancer Institute. 101(6):374-83. Abstract
Public Health Sciences Division
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.  2009.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.. Journal of the National Cancer Institute. 101(6):374-83. Abstract
Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, DiTommaso D, Karnofski K, Gulati R, Penson DF et al..  2008.  Quantifying the role of PSA screening in the US prostate cancer mortality decline.. Cancer causes & control : CCC. 19(2):175-81. Abstract
Prostatic Neoplasms
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.  2009.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.. Journal of the National Cancer Institute. 101(6):374-83. Abstract
Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, DiTommaso D, Karnofski K, Gulati R, Penson DF et al..  2008.  Quantifying the role of PSA screening in the US prostate cancer mortality decline.. Cancer causes & control : CCC. 19(2):175-81. Abstract
Prostate-Specific Antigen
Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, DiTommaso D, Karnofski K, Gulati R, Penson DF et al..  2008.  Quantifying the role of PSA screening in the US prostate cancer mortality decline.. Cancer causes & control : CCC. 19(2):175-81. Abstract
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.  2009.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.. Journal of the National Cancer Institute. 101(6):374-83. Abstract
Netherlands
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.  2009.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.. Journal of the National Cancer Institute. 101(6):374-83. Abstract
Models, Theoretical
Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, DiTommaso D, Karnofski K, Gulati R, Penson DF et al..  2008.  Quantifying the role of PSA screening in the US prostate cancer mortality decline.. Cancer causes & control : CCC. 19(2):175-81. Abstract
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.  2009.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.. Journal of the National Cancer Institute. 101(6):374-83. Abstract
Models, Statistical
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.  2009.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.. Journal of the National Cancer Institute. 101(6):374-83. Abstract
Middle Aged
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.  2009.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.. Journal of the National Cancer Institute. 101(6):374-83. Abstract
Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, DiTommaso D, Karnofski K, Gulati R, Penson DF et al..  2008.  Quantifying the role of PSA screening in the US prostate cancer mortality decline.. Cancer causes & control : CCC. 19(2):175-81. Abstract
Mass Screening
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.  2009.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.. Journal of the National Cancer Institute. 101(6):374-83. Abstract
Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, DiTommaso D, Karnofski K, Gulati R, Penson DF et al..  2008.  Quantifying the role of PSA screening in the US prostate cancer mortality decline.. Cancer causes & control : CCC. 19(2):175-81. Abstract
Male
Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, DiTommaso D, Karnofski K, Gulati R, Penson DF et al..  2008.  Quantifying the role of PSA screening in the US prostate cancer mortality decline.. Cancer causes & control : CCC. 19(2):175-81. Abstract